ECOLAB INC. Quarterly Report for Q1 Ended Mar 31, 2024

Summary

Ecolab Inc. reported a strong first quarter for 2024, with net sales increasing by 5% year-over-year to $3.75 billion, driven by a 5% increase in organic sales. The company demonstrated significant profit growth, with reported operating income up 47% to $517.9 million and net income attributable to Ecolab soaring 77% to $412.1 million. This robust performance was supported by an improved gross margin of 43.3% (up from 38.3% in the prior year) due to lower delivered product costs and effective pricing strategies. The company's strategic focus on efficiency and pricing power appears to be paying off, leading to substantial earnings per share growth. Ecolab also managed its debt effectively, reducing total debt by approximately $630 million in the quarter and maintaining a healthy net debt to EBITDA ratio of 2.2. Looking ahead, Ecolab has agreed to sell its global surgical solutions business for $950 million, which is expected to close in the second half of 2024 and generate a pre-tax gain, further strengthening its financial position and allowing for continued strategic investments.

Key Highlights

• 1Net sales increased 5% to $3.75 billion, with organic sales also up 5%.
• 2Reported operating income increased 47% to $517.9 million, and net income attributable to Ecolab grew 77% to $412.1 million.
• 3Gross margin improved significantly to 43.3% from 38.3% in the prior year, driven by lower costs and strong pricing.
• 4Diluted EPS increased 74% to $1.43, with adjusted diluted EPS up 52% to $1.34.
• 5The company reduced its total debt by $630 million during the quarter, ending with $7.5 billion in total debt.
• 6Cash provided by operating activities was strong at $649.4 million, a significant increase from $198.2 million in the prior year.
• 7Ecolab announced the sale of its global surgical solutions business for $950 million, expected to close in the second half of 2024.

Frequently Asked Questions